Skip to main
HUMA
HUMA logo

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc. is enhancing its commercial viability by scaling manufacturing capabilities and expanding access to hospitals, which are projected to be pivotal factors driving revenue growth through 2026. The company's significant advancements in trauma vascular repair bolster its reputation within both military and civilian healthcare markets, reinforcing its competitive positioning. Furthermore, the validation of its biologic conduit’s robust performance in demanding clinical scenarios enhances investor confidence and suggests strong potential for widespread adoption of its innovative biotechnology platform.

Bears say

Humacyte Inc. is facing financial challenges characterized by a high burn rate and ongoing losses that raise concerns about its sustainability and ability to fund operations in the long term. The company's reliance on equity financing to cover operational costs may dilute existing shareholders, which could negatively impact stock performance. Additionally, uncertainties surrounding the regulatory approval process for its innovative products contribute to a cautious outlook, as delays could further hinder revenue generation and overall market confidence.

Humacyte (HUMA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Humacyte (HUMA) has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.